Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth
Nasus Pharma appointed pharmaceutical industry veteran Brendan P. O'Grady as Chief Executive Officer, effective July 27, 2026, succeeding Dan Teleman. Mr. O'Grady, former CEO of Teva USA and Assertio Holdings, is tasked with leading the company's next phase of growth, focusing on the commercial potential of lead asset NS002.
Key figures
- Drug Name
- NS002
- Data readout
- Q1 2027
- Market size usd
- $2 billion
- Pivotal trial start
- Q4 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.